Protara therapeutics, inc. (PRTO)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13
Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,948

-

-

-

Operating expense:
Research & development

3,064

3,034

206

2,120

1,077

2,663

2,354

2,760

4,071

3,213

10,336

3,891

4,246

4,437

4,842

5,241

4,349

3,580

3,078

3,090

2,633

1,874

1,773

1,596

1,189

971

General & administrative

7,094

3,714

1,385

3,266

450

2,722

2,268

2,240

2,294

2,377

1,970

2,095

2,234

2,429

2,324

2,613

2,470

2,607

2,004

1,891

1,987

1,399

1,041

912

744

943

Total operating expenses

10,159

6,748

1,591

5,386

1,528

5,385

4,622

5,000

6,365

5,590

12,306

5,986

6,480

6,866

7,166

7,854

6,819

6,187

5,082

4,981

4,620

3,273

2,814

2,508

1,933

1,914

Operating loss

-10,159

-6,748

-1,591

-5,386

-1,528

-5,385

-4,622

-5,000

-6,365

-5,590

-12,306

-5,986

-6,480

-6,866

-7,166

-7,854

-6,819

-6,187

-5,082

-4,981

-4,620

-3,273

134

-2,508

-1,933

-1,914

Other (income) expense, net
Interest (income) expense, net

99

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investment income

-

-

53

73

-

125

113

106

92

98

83

46

32

38

46

53

56

33

34

37

40

-

10

3

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

29

828

171

Other income, net

-

-

2

-2

-

1

-1

15

192

-59

-84

332

-50

-134

13

-104

211

-188

-335

-128

0

10,495

-5,325

-29

-70

-189

Total other (income) expense, net

99

-

55

71

-

126

112

121

284

39

-1

378

-18

-96

59

-51

267

-155

-301

-91

40

10,506

-5,315

-55

-898

-18

Net Loss

-10,060

-6,612

-1,536

-5,315

-1,528

-5,259

-4,510

-4,879

-6,081

-5,551

-12,307

-5,608

-6,498

-6,962

-7,107

-7,905

-6,552

-6,342

-5,383

-5,072

-4,580

7,233

-5,181

-2,563

-2,831

-2,103

Weighted Average Shares Outstanding, basic and diluted

5,560

-39,809

19,585

19,585

2,627

-51,363

17,824

17,674

17,674

17,679

17,574

17,207

16,636

16,596

16,582

16,561

16,507

16,490

16,466

16,449

16,448

11,536

240

240

240

233

Foreign currency translation adjustment

-

-

-2

-2

-

0

0

-3

2

6

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gain on available-for-sale investments

-

-

-

-

-

1

3

8

8

-13

0

-7

0

-8

-2

-2

23

-17

3

3

6

-

12

-23

-

-1

Comprehensive loss

-

-

-1,538

-5,317

-

-5,258

-4,507

-4,874

-6,071

-5,558

-12,307

-5,615

-6,498

-6,970

-7,109

-7,907

-6,529

-6,359

-5,380

-5,069

-4,574

-

-5,169

-2,586

-

-2,104

Net loss

-10,060

-6,612

-1,536

-5,315

-1,528

-5,259

-4,510

-4,879

-6,081

-5,551

-12,307

-5,608

-6,498

-6,962

-7,107

-7,905

-6,552

-6,342

-5,383

-5,072

-4,580

7,233

-5,181

-2,563

-2,831

-2,103

Accretion of convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

6,747

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,221

-2,277

1,897

1,512

1,540

Net loss attributable to common stockholders

-

-

-1,536

-5,315

-

-

-4,510

-4,879

-6,081

-5,551

-19,054

-5,608

-6,498

-6,962

-7,107

-7,905

-6,552

-6,342

-5,383

-5,072

-4,580

6,566

-7,458

-4,460

-4,343

-3,643

Net loss per share, basic and diluted

-1.81

-29.22

-0.08

-0.27

-0.58

-44.93

-0.25

-0.28

-0.34

-0.33

-1.08

-0.33

-0.39

-0.41

-0.43

-0.48

-0.40

-0.38

-0.33

-0.31

-0.28

64.48

-31.00

-18.55

-18.09

-15.60

Allocated share-based compensation

-

-

96

101

-

-

904

922

821

768

747

867

845

844

687

946

866

670

611

476

407

225

185

32

17

-

Realized losses from forward foreign currency contracts

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4

-10

6

-38

0

-14

0

-

-

-

-

-

Unrealized gains (losses) from forward foreign currency contracts

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

-53

178

-111

-314

-112

0

-

-

-

-

-

Total

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2

-63

184

-149

-314

-126

0

-

-

-

-

-

Comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,831

-

Research and Development Expense [Member]
Allocated share-based compensation

-

-

-26

4

-

-

298

312

267

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and Administrative Expense [Member]
Allocated share-based compensation

-

-

122

97

-

-

606

610

554

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-